Markets

ZS Pharma prices IPO at $18, above the range

An image of a person using a calculator to do paperwork
Credit: Shutterstock photo

ZS Pharma, a late-stage biotech developing a treatment for excess potassium (hyperkalemia), raised $107 million by offering 5.9 million shares (vs. 5 million originally planned) at $18, above the $15 to $17 range. ZS Pharma will list on the NASDAQ under the symbol ZSPH. J.P. Morgan and Credit Suisse acted as joint bookrunners on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

IPOs